Table 5.

 Summary of adverse events

Percentage of patients	Treatment group
	Aprepitant 125/80 mg + standard therapy (n = 150)	Aprepitant 40/25 mg + standard therapy (n = 148)	Standard therapy (n = 151)
With ≥1 adverse event	99.3	99.3	99.3
With drug‐related adverse events†	23.3	18.9	19.9
With serious adverse events	6.0	6.8	2.6
Discontinued due to adverse events	0.7	1.4	0.0
With most common adverse events‡
Anorexia	48.0	59.5	53.6
Constipation	38.7	42.6	45.7
Hiccups	43.3	33.1	37.1
Malaise	25.3	31.8	17.9
Diarrhea	21.3	26.4	26.5
Nausea	36.7	41.9	35.1
Vomiting	14.7	14.9	19.2
Pyrexia	9.3	12.8	13.9
Insomnia	4.7	7.4	10.6
With febrile neutropenia	4.0	4.1	6.6

†Determined by the investigator as possibly drug related, probably drug related or definitely drug related. ‡Incidence ≥10% in at least one group. There were no statistically significant (P > 0.1) differences in the risk of adverse events between the treatment groups. Statistical testing was not performed for individual common adverse events. Nausea and vomiting were considered adverse events if they occurred after day 5 of the study, or at any time if they were determined by the investigator to be serious or drug related, or if they resulted in discontinuation.